ClinicalTrials.gg

Program

vipoglanstat

Also written as “GS-248”, “Vipoglanstat” and “Formulation A GS-248”.

Its studies are mostly in Endometriosis · Scleroderma, Systemic, led by Gesynta Pharma AB.

Furthest: phase 2, since Jan 28, 20214 company-led studies, 1 open or runningNext primary completion: Jun 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Gesynta Pharma AB41 open or runningphase 2since Jan 28, 2021Jul 23, 2019Jun 2027phase 2 · NCT07260669

Also a collaborator on its studies: ergomed and ctc-clinical-trial-consultants-ab.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 23, 2019First study: phase 1 study in HealthyFirst studyNCT04036227 · 72 enrolled · Sweden
  2. May 27, 2020Phase 1 study in PharmacokineticNCT04617509 · 14 enrolled · Sweden
  3. Jan 28, 2021Phase 2 study in Scleroderma, SystemicNCT04744207 · 94 enrolled · Belgium, Netherlands, Poland and more
  4. Sep 29, 2025Phase 2 study in EndometriosisNCT07260669 · 213 enrolled · Bulgaria, Czechia, Hungary and more

Ahead

  1. Jun 2027Primary completion: phase 2 study in EndometriosisNCT07260669

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07260669Endometriosis · Bulgaria, Czechia, Hungary and more2Active, not recruitingJun 2027213
NCT04744207Scleroderma, Systemic · Belgium, Netherlands, Poland and more2CompletedJun 15, 202294
NCT04617509Pharmacokinetic · Sweden1CompletedMay 27, 202014
NCT04036227Healthy · Sweden1CompletedDec 20, 201972

How it is read

Names in the registry

  • “GS-248”, 2 entries
  • “Vipoglanstat”, 1 entry
  • “Formulation A GS-248”, 1 entry
  • “Formulation B GS-248”, 1 entry

Codes read as this program: GS248.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.